Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

User noticed receding temples, used minoxidil and microneedling with positive results. Added saw palmetto and eucapil, experienced shedding and thinner hairline, but no side effects.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

People are discussing switching to Indian generic dutasteride tablets like Dutanol and Dutaheal due to cost concerns, with some users reporting positive results when taken with a high-fat meal. Users have shared experiences with different brands, noting varying effectiveness and side effects compared to finasteride.

A user shared their 2-year progress using finasteride every other day with no side effects. Others discussed their experiences, shedding cycles, and patience with the treatment.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

The conversation is about finding genuine sources to buy Pyrilutamide in India and possibly importing it as a group to reduce costs. The user seeks advice on shipping without prescription issues.

Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.

The user is excited about an upcoming update for GT20029, expected in March. They express frustration with the negativity on Reddit.

The conversation discusses using RU58841 with primobolan or masteron to protect hair while on steroids, alongside dutasteride. Users suggest caution with these compounds due to potential hair loss and discuss alternatives like nandrolone and EQ for better hair safety.

Hair loss discussion focuses on adding an anti-androgen to stack with topical finasteride. Eucapil (fluridil) is suggested for its safety and minimal side effects.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Hair loss discussion includes treatments like Minoxidil, finasteride, and RU58841. Platelet rich plasma treatment is considered expensive but cheaper than hair transplant.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.

The user experienced gynecomastia from finasteride, used raloxifene to treat it, and is now taking both without new gyno symptoms but also without hair regrowth. They are seeking others' experiences with this combination and its effects on hair.